Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2019
At a glance
- Drugs Tadalafil (Primary)
- Indications Diabetic cardiomyopathy; Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- Acronyms RECOGITO
- 09 Jul 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 27 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.